G20.10
Conditions
Interventions
Group 1: The duration of participation is planned for 6 months for all study participants. The study visits are the same for all 3 groups of participants. They take place on site at the respective stu
Sponsors
Abteilung für Molekulare Neurologie, Universitätsklinik Erlangen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. idiopathic parkinsonian syndrome (H&Y II-III). 2. UPDRS III > 13 with involvement uEx 3. ability to walk > 10 m without support 4. minimal mental status test (MMST) score = 26. 5. willingness of the study participant to take up therapy measures (e.g., drug therapy, exercise therapy) (already prior to study participation).
Exclusion criteria
Exclusion criteria: 1. tremor dominant parkinsonian syndrome 2. risk of falling with high injury potential 3. if included, current or planned inpatient stay within the next two weeks 4. severe ON freezing 5. severe internistic/orthopedic/psychological comorbidities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Close-In-, Intermis-, Close-Out-Analysis: MDS-UPDRS III | — |
Secondary
| Measure | Time frame |
|---|---|
| Healthstate: MDS-UPDRS (II, IIII, IV), Lindop-PAS, Mini-Best-Test,10m-Walk-Test, ABC-Scale, PASE, ErFOF-Q, CGI-C, Quality of Life: EQ-5D-5L, PDQ39, Health-Literacy in Parkinson's Disease (ErPDKT, ErAIC-PD, self-designed), Patient Souvereignity (SSE, PAM-13D, Decision-Self-Efficacy Scale) | — |
Countries
Germany
Contacts
Public ContactFranziska Müller
Abteilung für Molekulare Neurologie
Outcome results
None listed